• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ImmunityBio, Inc. - Common Stock (NQ:IBRX)

    6.485 +0.035 (+0.54%)
    Streaming Delayed Price Updated: 12:26 PM EST, Jan 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 20,698,542
    Open 6.660
    Bid (Size) 6.480 (2,400)
    Ask (Size) 6.490 (2,600)
    Prev. Close 6.450
    Today's Range 6.260 - 6.660
    52wk Range 1.830 - 8.280
    Shares Outstanding 391,156,513
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research ↗
    Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified. 
    Via Stocktwits
    Topics Death ETFs
    Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Economy Stocks

    Performance

    YTD
    +221.0%
    +221.0%
    1 Month
    +203.7%
    +203.7%
    3 Month
    +143.8%
    +143.8%
    6 Month
    +144.7%
    +144.7%
    1 Year
    +107.2%
    +107.2%

    More News

    Read More
    News headline image
    $5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!
    Via AB Newswire
    News headline image
    Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month ↗
    Via The Motley Fool
    Topics Stocks
    IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing ↗
    Via Stocktwits
    Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗
    Via Stocktwits
    IBRX Stock Continues Rally — What’s Driving The Optimism Today? ↗
    Via Stocktwits
    News headline image
    IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz ↗
    Via Stocktwits
    Topics Death
    News headline image
    ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗
    Via The Motley Fool
    Topics Stocks
    News headline image
    Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗
    Via The Motley Fool
    Topics Stocks
    Which stocks are most active on Tuesday? ↗
    Via Chartmill
    News headline image
    ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    Nasdaq, S&P 500 Futures Slide As Trump Ramps Up Greenland Threats: Why NFLX, CRML, TSLA, VERO, SRXH Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Why Is ImmunityBio Stock Back In Retail Spotlight Today? ↗
    Via Stocktwits
    Nasdaq, S&P 500 Futures Slide On Greenland Tensions: Why NVDA, MU, IBRX, CRML And VERO Are On Traders’ Radar Today ↗
    Via Stocktwits
    Topics Stocks
    News headline image
    Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year ↗
    Via The Motley Fool
    Topics Stocks
    Which stocks are experiencing notable movement on Friday? ↗
    Via Chartmill
    News headline image
    Why ImmunityBio Stock Is Skyrocketing Again Today ↗
    Via The Motley Fool
    Curious about the most active stocks on Friday? ↗
    Via Chartmill
    Keep an eye on the top gainers and losers in Friday's session. ↗
    Via Chartmill
    Friday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
    From ImmunityBio, Inc.
    Via Business Wire
    News headline image
    Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗
    Via The Motley Fool
    Topics Earnings Stocks

    Frequently Asked Questions

    Is ImmunityBio, Inc. - Common Stock publicly traded?
    Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
    What exchange does ImmunityBio, Inc. - Common Stock trade on?
    ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
    The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
    What is the current price of ImmunityBio, Inc. - Common Stock?
    The current price of ImmunityBio, Inc. - Common Stock is 6.485
    When was ImmunityBio, Inc. - Common Stock last traded?
    The last trade of ImmunityBio, Inc. - Common Stock was at 01/26/26 12:26 PM ET
    What is the market capitalization of ImmunityBio, Inc. - Common Stock?
    The market capitalization of ImmunityBio, Inc. - Common Stock is 2.54B
    How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
    ImmunityBio, Inc. - Common Stock has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.